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Camostat mesilate is in widespread clinical use mainly to treat chronic pancreatitis, and drug-induced
lung injury has not been previously reported. However, pulmonary inﬁltration with peripheral blood
eosinophilia appeared after taking camostat mesilate for ten days. The histological ﬁndings showed
eosinophilic inﬁltration into the alveolar space and interstitum, and drug lymphocyte stimulation test of
peripheral blood was positive. Both peripheral blood eosinophilia and pulmonary involvements
improved two weeks later with the cessation of this drug. To the best of our knowledge, this case is the
ﬁrst report of camostat mesilate-induced acute eosinophilic pneumonia.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Any drugs can cause lung injury and their clinical conditions are
miscellaneous. Camostat mesilate is in widespread clinical use
mainly to treat chronic pancreatitis and the number of people who
takes this drug during one year is estimated at about a hundred
thousand. Generally this drug is believed to be safe and secure;
indeed, camostat mesilate-induced lung injury has not been re-
ported so far. Here we report the ﬁrst case of camostat mesilate-
induced acute eosinophilic pneumonia.1.1. Case presentation
A 65-year-old man was given camostat mesilate (600 mg/day)
for ten days due to pancreatitis after endoscopic retrograde chol-
angiopancreatography for the evaluations of cholangitis andid; DLST, drug lymphocyte
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Ltd. This is an open access article upancreatic cyst. One week later, he was admitted to our hospital
suffering from low grade fever, though abdominal symptom due to
pancreatitis had been improved. Chest radiograph revealed bilat-
eral ﬁne nodular opacities in the middle and lower ﬁelds (Fig. 1).
Arterial blood gas analysis (ambient air) indicated that pH 7.466,
PaCO2 32.8 mmHg and PaO2 63.7 mmHg. Results of additional
laboratory examination were as follows: white blood cell count
7700/mL (eosinophils 52%), C-reactive protein 18.5 mg/dL (normal
range, <0.3 mg/dL), lactate dehydrogenase 250 IU/L (normal range,
<225 IU/L), IgE-RIST 166 IU/mL (normal range, <170 IU/mL), sur-
factant proteins-D 54.6 ng/mL (normal range, <110 ng/mL), Krebs
von den Lungen-6 137 U/mL (normal range, <500 U/mL), anti-
nuclear antibody < 20 index (normal range, <20 index),
cytoplasmic-anti-neutrophil cytoplasmic antibody < 10 EU, and
perinuclear-anti-neutrophil cytoplasmic antibody < 10 EU. Sputum
culture was negative for pathogenic bacteria and acid-fast bacilli.
Pulmonary function test indicated obstructive abnormality (FEV1.0/
FVC¼ 69.6%). High-resolution computed tomography (HRCT) of the
lung showed bilateral ground glass opacities (GGO) and septal line
thickenings with subpleural distribution in the middle and lower
lobes (Fig. 2). The bronchoalveolar lavage ﬂuid (BALF) results were
as follows: total cell counts 3.3  105/mL, macrophages 22%, eo-
sinophils 77%, and lymphocytes 1%. We found infective etiologies
including viral, tuberculous and fungal infections negative. Parasitic
analysis for faecal specimen was also negative and there was nonder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Chest radiograph obtained on admission showing ﬁne nodular opacities in both
middle and lower lung ﬁelds.
Fig. 2. High-resolution computed tomography showed bilateral ground glass opacities
and septal line thickenings with subpleural distribution in the middle and lower lobes.
Fig. 3. Transbronchial lung biopsy specimens revealed the accumulations of eosino-
phils and macrophages in the alveolar space and interstitum with the mild edema of
alveolar septa (Hematoxylin and Eosin staining  100).
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specimens revealed the accumulations of eosinophils in the alve-
olar space and interstitum with the mild edema of alveolar septa
(Fig. 3). In addition, the drug lymphocyte stimulation test (DLST) of
peripheral blood for camostat mesilate was positive (stimulation
index 493%). His temperature decreased and blood eosinophilia
and pulmonary involvements were improved two weeks later with
the cessation of the drug. Thus, we concluded the case was acute
eosinophilic pneumonia induced by camostat mesilate.2. Discussion
Recently drug-induced lung injuries have been increasing as
various drugs developed, and such clinical conditions are diverse.
However, camostat mesilate and its analogous drugs, serine pro-
tease inhibitors, have rarely caused lung injury.
The mechanism of pathogenesis is broadly divided into two
categories i.e. toxic reaction and allergic reaction [1,2]. The present
case was thought to be allergic reaction. Allen proposed the ﬁve
criteria for drug-induced eosinophilic lung disease [3]. Clinically
the patient should: (A) have no other likely cause of lung disease,
(B) have symptoms consistent with the suspect drug, (C) have a
time course compatible with drug-induced lung disease, (D) have
tissue or BALF ﬁndings compatible with drug-induced lung disease,
and (E) improve after the drug is discontinued. This case fulﬁlled
these ﬁve criteria and so is a deﬁnitive case.
Pietra and coworkers indicated that drug-induced eosinophilic
lung disease has two patterns; acute and chronic form [4]. It was
also reported that the opacities of chronic patterns were persistent
despite the cessation of causative agents and the administration of
oral prednisolone [5,6]. In this case, clinical symptoms appeared
after prescribing camostat mesilate for ten days. HRCT ﬁndings
showed mainly GGO and septal line thickening with subpleural
distribution in the middle and lower lobes. Dominant histological
ﬁndings are characterized by accumulations of eosinophils and
macrophages and inﬁltrations of eosinophis, lymphocytes and
plasma cells in the alveolar septa. All these ﬁndings are consistent
with acute form. Indeed, the clinical condition of the present case
was improved only by the cessation of camostat mesilate. There-
fore, we speculate that early diagnosis and therapeutic intervention
are very important for favorable outcome.
Suzuki and coworkers advocates that drug provocation test was
the most useful for the detection of responsible agents [7,8].
Although DLST has several technical problems such as lymphocyte
stimulation by drug itself (mitogenic activity), lymphocyte inhibi-
tion [9], criteria for stimulation index, and the effects of interme-
diate metabolites of the drug, we embraced the research by Pitchler
and coworkers that if stimulation index was more than 300%, DLST
was positive [10]. As the stimulation index of this case was ~500%,
we determined the result of DLST was positive. Thus, we diagnosed
this case as camostat mesilate-induced acute eosinophilic
S. Ota et al. / Respiratory Medicine Case Reports 19 (2016) 21e23 23pneumonia.
The causative agents of drug-induced eosinophilic lung disease
were wide-ranging. In fact, about 160 drugs which can cause
eosinophilic pneumonia have been reported by 2015 in theweb site
of PNEUMOTOX ONLINE (http://www.pneumotox.com); however,
camostat mesilate-induced lung injury has not been reported so far.
Further, there was no mention of camostat mesilate-induced lung
injury in the website of Pharmaceuticals and Medical Devices
Agency (PMDA) of Japan (http://www.pmda.go.jp) nor PubMed
(http://www.ncbi.nlm.nih.gov/pubmed). To the best of our knowl-
edge, this case is the ﬁrst report of camostatmesilate-induced acute
eosinophilic pneumonia. The possibility of drug-induced lung
injury by camostat mesilate should be taken into account.
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